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Disclosures
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I have nothing to disclose concerning possible financial or
personal relationships with commercial entities that may
have a direct or indirect interest in the subject matter of
this presentation

Objectives
Review select oral oncolytic approvals
in 2019

Discuss the challenges associated
with oral oncolytics
Identify possible solutions to
challenges associated with oral
oncolytics
3

Background
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Historically, chemotherapy has been administered by
intravenous infusion in an oncology inpatient unit, clinic or
a physician’s office
First oral oncolytics approved in 1953

Mercaptopurine

Methotrexate

1953-2014: 29 agents approved in 61 years, averaging
~2 agents per year

2019: 7 agents approved in 1 year

It is estimated that 25%-30% in the research pipeline
are oral

Weingart SN et al. 2008;6 Suppl 3:S1-14.

Advantages
Increased control and
convenience
Potential increase in the quality
of life
Potential reduction in travel costs
and use of healthcare resources
Sustained medication exposure

Disadvantages
Lack of coordinated care
Increased errors
Nonadherence
Limited and difficulty monitoring
5

Weingart SN et al. 2008;6 Suppl 3:S1-14.

Oral Oncolytic Approvals in
2019
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Cabozantinib: Hepatocellular carcinoma, January 14, 2019
Trifluridine-tipiracil: Gastric or gastroesophageal junction
(GEJ) adenocarcinoma, February 22, 2019
Alpelisib: Breast cancer, May 24, 2019
Erdafitinib: Urothelial carcinoma, April 12, 2019
Darolutamide: Prostate cancer, July 30, 2019
Apalutamide: Prostate cancer, September 17, 2019
Lenvatinib: Endometrial carcinoma, September 17, 2019
Niraparib: Ovarian, fallopian tube, or primary peritoneal
cancer, October 23, 2019
Enzalutamide: Prostate cancer, December 16, 2019

Cabozantinib (Cabometyx®)
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Indication: Patients with hepatocellular carcinoma after
prior therapy with sorafenib
Cabozantinib [package insert]. Alameda, CA: Elexisis; 2019

Cabozantinib (Cabometyx®)
Dose
• 60 mg po
daily
without
food

8

Strengths
• 60 mg
• 40 mg
• 20 mg

Drug-Drug
Interactions

Adverse Effects

• Strong CYP3A4
inhibitors: If can’t
avoid, reduce
cabozantinib dose
Strong CYP3A4
inducers: If can’t
avoid, increase
cabozantinib dose

• Hemorrhage
• Perforations and
fistulas
• Thrombotic events
• Hypertension and
hypertensive crisis
• Diarrhea
• Palmar-plantar
erythrodysesthesia
(PPE)
• Proteinuria
• Osteonecrosis of the
jaw
• Wound complications
• Reversible posterior
leukoencephalopathy
syndrome

Cabozantinib [package insert]. Alameda, CA: Elexisis; 2019

Cabozantinib (Cabometyx®)
Pearls
• Cabometyx tablets ≠ cabozantinib capsules
• Do not give with food
• ≥1 hour before or ≥2 hours after eating
• Take missed dose if <12 hours to next dose
• Hold ≥28 days prior to surgery
• Diarrhea (any grade: 63%, Grade 3: 11%):
• Intolerable Grade 2, Grade 3, or Grade 4: Hold until Grade 1; resume
at ↓ dose
• PPE (any grade: 44%, grade 3: 13%):
• Intolerable Grade 2 or Grade 3: Hold until Grade 1; resume at ↓ dose
• Prophylaxis: Moisturizing creams containing keratolytics
• Treatment: Urea, clobetasol, pain control
• Hypertension and hypertensive crisis (any grade: 36%, Grade 3:17%):
• Uncontrolled hypertension: Hold; resume at ↓ dose once controlled
• Severe hypertension not medically manageable or hypertensive crisis:
Discontinue
9

Cabozantinib [package insert]. Alameda, CA: Elexisis; 2019

Trifluridine-Tipiracil (Lonsurf®)
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Indication: Patients with metastatic gastric or GEJ
adenocarcinoma previously treated with ≥2 prior lines of
chemotherapy that included a fluoropyrimidine, a platinum,
either a taxane or irinotecan, and if appropriate, HER2/neutargeted therapy
Trifluridine-Tipiracil [package insert]. Princeton, NJ: Taiho; 2019

Trifluridine-Tipiracil (Lonsurf®)
Dose

Strengths

• 35 mg/m2/dose • 15 mg
trifluridine/
orally twice
6.14 mg
daily with food
tipiracil
on
• 20 mg
• Days 1-5
trifluridine/
• Days 8-12
8.19 mg
• Every 28
tipiracil
days
• Dosing based
on trifluridine
• Round nearest
5 mg
• Maximum: 80
mg
11

Drug-Drug
Interactions
• None in in
vitro studies

Adverse Effects
•

•

Severe
myelosuppression
(neutropenia,
anemia,
thrombocytopenia,
and febrile
neutropenia)
Gastrointestinal
toxicity

Trifluridine-Tipiracil [package insert]. Princeton, NJ: Taiho; 2019

Trifluridine-Tipiracil (Lonsurf®)
Pearls
• If stored outside of original bottle, discard after 30 days
• Dosing schedule:
• Monday to Friday
• 2 weeks on, 2 weeks off
• Complete blood cell (CBC) prior to and on Day 15 each cycle
• Hold for any of the following:
• Absolute neutrophil count (ANC) <500/mm3 or febrile neutropenia
• Platelets <50,000/mm3
• Grade 3 or 4 non-hematologic adverse effects
• Recover then ↓ dose by 5 mg/m2/dose
• Maximum of 3 dose reductions
• Do not ↑ dose after reduction
• 20 mg/m2 po BID not tolerable: Permanently discontinue
12

Trifluridine-Tipiracil [package insert]. Princeton, NJ: Taiho; 2019

Trifluridine-Tipiracil (Lonsurf®)
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Tips & Tools. LONSURF® (trifluridine and tipiracil) tablets. https://www.lonsurf.com/patient-resources/tools.

Alpelisib (Piqray®)
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In combination with fulvestrant for postmenopausal
women, and men, with hormone receptor (HR)-positive,
human epidermal growth factor receptor 2 (HER2)negative, PIK3CA-mutated, advanced or metastatic breast
cancer
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019

Alpelisib (Piqray®)
Dose
• 300 mg (two
150 mg filmcoated tablets)
po daily with
food
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Strengths
• 50 mg
• 150 mg

Drug-Drug
Interactions
• CYP3A4
inducer: Avoid
• BCRP
inhibitors:
Avoid, if unable
to use
alternative
drugs, closely
monitor for
increased
adverse
reactions
• CYP2C9
substrates:
Closely monitor

Adverse Effects
• Severe
hypersensitivity
• Severe
cutaneous
reactions
• Hyperglycemia
• Pneumonitis
• Diarrhea

Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019

Alpelisib (Piqray®)
Dose Level

Dose1

Number and Strength of Tablets

Starting dose

300 mg once daily

Two 150 mg tablets

First-dose reduction

250 mg once daily

One 200 mg tablet and one 50 mg
tablet

Second-dose reduction

200 mg once daily

One 200 mg tablet

1Only
2If

one dose reduction is permitted for pancreatitis
further dose reduction below 200 mg once daily is required

Severity of Diarrhea

Recommendations

Grade 1 (increase of <4
stools per day over
baseline)

•

Initiate medical therapy and monitor

Grade 2 (increase of 4-6
stools per day over
baseline )

•
•

Initiate or intensify medical therapy and monitor
Hold until Grade ≤1: Resume at same dose level

Grade 3 (increase of ≥7
stools per day over
baseline) and Grade 4
16
(life-threatening
consequences)

•

Initiate or intensify appropriate medical therapy and
monitor as clinically indicated. Interrupt dose until
recovery to Grade ≤1, then resume at the next lower
dose level
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019

Alpelisib (Piqray®)
Severity of
Hyperglycemia
Grade 1 (FPG
>ULN-160
mg/dL)
Grade 2 (FPG
>160-250
mg/dL)
Grade 3 (>250500 mg/dL)

Grade 4 (>500
mg/dL)
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Recommendations
•
•

Initiate or intensify anti-diabetic treatment
SOLAR-1 trial:
• Metformin 500 mg po daily  500 mg po twice daily  500
mg po with breakfast and 1000 mg po with dinner  1000
mg po twice daily

•

Follow Grade 1 recommendations

•

Follow Grade 1 recommendations and consider additional antidiabetic medications X1-2 days until improvement
FPG ↓ to ≤160 mg/dL within 3 to 5 days: Resume at 1 lower dose
level
• Not within 3-5 days: Consult physician
• Not within 21 days: Permanently discontinue

•

•
•
•

Follow Grade 1 recommendations, re-check FPG within 24 hours
and as clinically indicated
FPG ↓ to ≤500 mg/dL: Follow Grade 3 recommendations
FPG >500 mg/dL: Permanently discontinue
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019

Alpelisib (Piqray®)
Severity of Rash

Recommendations

Grade 1
(<10% body surface area (BSA) with
active skin toxicity)

•
•

Topical corticosteroid treatment
Consider + oral antihistamine

Grade 2
(10-30% BSA with active skin
toxicity)

•

Initiate or intensify topical corticosteroid +
oral antihistamine
Consider + low dose systemic corticosteroid

•

•

Initiate or intensify topical/systemic
corticosteroid + oral antihistamine
treatment
Once ≤Grade 1:
• 1st occurrence: Resume at the same
dose level 2nd occurrence: Resume at
next lower dose level

•

Permanently discontinue

•
Grade 3 (e.g., severe rash not
responsive to medical management)
(>30% BSA with active skin toxicity)

Grade 4 (e.g., severe bullous,
blistering or exfoliating skin
conditions)
(any % BSA associated with
extensive superinfection, with IV
antibiotics indicated; life-threatening
18 consequences)

Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019

Alpelisib (Piqray®)
Pearls
• Take with food
• Missed dose: Take up to 9 hours after usual time
• Hyperglycemia (any grade: 6%, Grade 3: 33%)
• Monitor blood glucose and/or FPG
• First 2 weeks: At least weekly
• Thereafter: At least 1X every 4 weeks, and as clinically indicated
• Hyperglycemia occurs: As clinically indicated, and ≥ 2X weekly
until normal
• During anti-diabetic therapy: At least weekly X 8 weeks 
biweekly and as clinically indicated
• Monitor HbA1c every 3 months and as clinically indicated
• Diarrhea: (any grade: 58%, Grade 3: 7%)
• Pneumonitis: Signs and symptoms
19

Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019

Erdafitinib (Balversa®)
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Patients with locally advanced or metastatic urothelial
carcinoma with susceptible fibroblast growth factor receptor
3 (FGFR3) or FGFR2 genetic alterations, when the disease
has progressed during or following platinum-containing
chemotherapy, including within 12 months of neoadjuvant
or adjuvant platinum-containing chemotherapy
Erdafitinib [package insert]. Northbrook, IL: Astellas; 2019

Erdafitinib (Balversa®)
Dose

Strengths

• 3 mg
• 8 mg (two 4
mg tablets) po • 4 mg
• 5 mg
daily
• ↑to 9 mg (three
3 mg tablets)
po daily based
on serum
phosphate
(PO4) levels
and tolerability
at 14-21 days

21

Drug-Drug
Interactions

Adverse Effects

Avoid, if not possible, • Hyperphosphat
monitor adverse
emia
reactions and consider • Ocular
dose modifications:
disorders
• Strong CYP2C9 or
CYP3A4 inhibitors
and inducers
• Moderate CYP2C9
or CYP3A4 inducers
• Serum phosphate
level-altering
agents
• CYP3A4 substrates
• OCT2 substrates
• P-gp substrates
Erdafitinib [package insert]. Northbrook, IL: Astellas; 2019

Erdafitinib (Balversa®)

Dose
9 mg ➝ (three
3 mg
tablets)
8 mg ➝ (two
4 mg
tablets)

1st Dose
Reduction

2nd Dose
Reduction

3rd Dose
Reduction

4th Dose
Reduction

5th Dose
Reduction

8 mg (two 4
mg
tablets)

6 mg
(two 3 mg
tablets)

5 mg
(one 5 mg
tablet)

4 mg
(one 4 mg
tablet)

Stop

6 mg
(two 3 mg
tablets)

5 mg
(one 5 mg
tablet)

4 mg
(one 4 mg
tablet)

Stop

Phosphate Levels

Dose
Adjustment

5.6-6.9 mg/dL

None

•

Continue

7.0-9.0 mg/dL

Hold

•
•
•

Hold until ↓ <5.5 mg/dL (or baseline)
Restart at same dose level
Hyperphosphatemia lasting >1 week: Consider
dose reduction

>9.0 mg/dL

Hold

•
•

Hold until ↓ <5.5 mg/dL (or baseline)
Restart at 1 dose level lower

•
•

Hold until ↓ <5.5 mg/dL (or baseline)
Restart 2 dose levels lower

>10.0 mg/dL or significant
alteration in baseline renal
function or Grade 3
hypercalcemia
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Hold

Recommendations

Erdafitinib [package insert]. Northbrook, IL: Astellas; 2019

Erdafitinib (Balversa®)
Grade of Central Serous
Retinopathy/Retinal Pigment
Epithelial Detachment
(CSR/RPED)

Recommendations
•

Grade 1: Asymptomatic; clinical
or diagnostic observations only
•

Hold until resolution
• Within 4 weeks: Resume at 1 lower dose
level
• Then, if no recurrence X 1 month: Consider
re-escalation
Not resolved but stable X2 consecutive eye
exams: Resume at 1 lower dose level

Grade 2: Visual acuity 20/40 or
better or ≤3 lines of decreased
vision from baseline

•
•

Hold until resolution
Resolves within 4 weeks: May resume at the
next lower dose level

Grade 3: Visual acuity worse
than 20/40 or >3 lines of
decreased vision from baseline

•

•

Hold until resolution
• Within 4 weeks: Resume 2 dose levels
lower
Recurs: Consider permanent discontinuation

Grade 4: Visual acuity 20/200
or worse in affected eye

•

Permanently discontinue
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Erdafitinib [package insert]. Northbrook, IL: Astellas; 2019

Erdafitinib (Balversa®)
Pearls
• Missed dose: Take as soon as possible. No double doses
• Hyperphosphatemia (any grade: 76%):
• Levels 14-21 days after initiation
• Monitor levels monthly
• Restrict phosphate intake to 600-800 mg daily
• >7.0 mg/dL: Consider adding oral phosphate binder until ↓ <5.5
mg/dL
• Ocular disorders (any grade: 25%, Grade 3: 3%)
• All patients should receive ocular demulcents as needed
• Eye exams
• During first 4 months: Monthly
• Thereafter: Every 3 months
24

Erdafitinib [package insert]. Northbrook, IL: Astellas; 2019

Lenvatinib (Lenvima®)
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In combination with pembrolizumab, for patients with
advanced endometrial carcinoma that is not microsatellite
instability-high (MSI-H) or mismatch repair deficient
(dMMR), who have disease progression following prior
systemic therapy and are not candidates for curative
surgery or radiation
Lenvatinib [package insert]. Woodcliff Lake, NJ: Eisai; 2019

Lenvatinib (Lenvima®)
Dose
• 20 mg po daily, •
in combination •
with
pembrolizumab
200 mg
administered
as an
intravenous
infusion over
30 minutes
every 3 weeks

26

Strengths
4 mg
10 mg

Drug-Drug
Interactions
• Drugs that
prolong the QT
interval: Avoid

Adverse Effects
Hypertension
Proteinuria
Diarrhea
QT interval
prolongation
• Hypocalcemia
• Impairment of
thyroid
stimulating
hormone
suppression/th
yroid
dysfunction
• Wound healing
complication
•
•
•
•

Lenvatinib [package insert]. Woodcliff Lake, NJ: Eisai; 2019

Lenvatinib (Lenvima®)
Adverse Reaction

Hypertension

Cardiac Dysfunction

Arterial thromboembolic event

Hepatotoxicity

Severity

Recommendations

•

Persists despite optimal antihypertensive
therapy: Hold
≤Grade 2: Resume at reduced dose

Grade 4

•

Permanently discontinue

Grade 3

•
•

Hold until ↓to Grade 0 to 1 or baseline
Depending on severity/persistence: Resume
at a reduced dose or discontinue

Grade 4

•

Permanently discontinue

Any

•

Permanently discontinue

•
•

Hold until ↓to Grade 0 to 1 or baseline
Depending on severity and persistence:
Either resume at a reduced dose or
discontinue
Hepatic failure: Permanently discontinue

Grade 3

Grade 3 or 4

•

•
Renal failure or impairment

27

Grade 3 or 4

•
•

Hold until ↓to Grade 0 to 1 or baseline
Depending on severity and persistence:
Resume at a reduced dose or discontinue
Lenvatinib [package insert]. Woodcliff Lake, NJ: Eisai; 2019

Lenvatinib (Lenvima®)
Adverse
Reaction
Proteinuria

Severity

≥2 g proteinuria in 24 hours

Recommendations
•
•
•

Hold until ≤2 g/24 hours
Resume at a reduced dose
Nephrotic syndrome: Permanent
discontinue

Gastrointestinal
perforation

Any

•

Permanently discontinue

Fistula formation

Grade 3 or 4

•

Permanently discontinue

>500 ms or >60 ms ↑from baseline

•
•

Hold until ≤480 ms or baseline
Resume at a reduced dose

•
•

Hold until resolved
Depending on severity and
persistence: Resume at a reduced
dose or discontinue

Persistent or intolerable Grade 2 or
3 adverse reaction
Grade 4 laboratory abnormality

•
•

Hold until ↓to Grade 0 to 1 or baseline
Resume at reduced dose

Grade 4 adverse reaction

•

Permanently discontinue

QT prolongation
Reversible
Posterior
Leukoencephalopa
thy Syndrome

Other

28

Any

Lenvatinib [package insert]. Woodcliff Lake, NJ: Eisai; 2019

Lenvatinib (Lenvima®)
Pearls
• Missed dose: Next dose is due within 12 hours, skip the missed dose
• If cannot swallow capsules, can take with medicine cup and liquid
• Hypertension: Monitor after 1 week  every 2 weeks X first 2 months, 
≥ monthly
• Proteinuria: Monitor prior to and periodically during treatment.
• ≥2+: Obtain 24-hour urine protein
• Diarrhea: Take loperamide 4 mg po, then 2 mg every 4 hours or after each
loose stool
• QT interval prolongation:
• Monitor and correct electrolyte abnormalities
• Monitor electrocardiograms in patients with cardiac conditions or on
agents that prolong the QT interval
• Impairment of thyroid stimulating hormone suppression/thyroid
dysfunction: Monitor prior to and monthly during treatment
• Treat hypothyroidism accordingly
• Wound healing complication: Hold for ≥6 days prior to surgery
29

Lenvatinib [package insert]. Woodcliff Lake, NJ: Eisai; 2019

Niraparib (Zejula®)

2

1

3
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Patients with advanced ovarian, fallopian tube, or primary
peritoneal cancer treated with three or more prior
chemotherapy regimens and whose cancer is associated
with homologous recombination deficiency (HRD)-positive
status
Niraparib [package insert]. Waltham, MA: Tesaro; 2019

Niraparib (Zejula®)

Dose
• 300 mg (three
100 mg
capsules) po
daily

Strengths
• 100 mg

Drug-Drug
Interactions
• No clinical
drug
interaction
studies have
been
performed

Adverse Effects
•

•
•

31

Myelodysplastic
syndrome/acute
myeloid
leukemia
Bone marrow
suppression
Cardiovascular
effects

Niraparib [package insert]. Waltham, MA: Tesaro; 2019

Niraparib (Zejula®)
Dose Modifications for Adverse Reactions
Dose Level

Dose

Starting dose

300 mg/day (three 100 mg capsules)

First dose reduction

200 mg/day (two 100 mg capsules)

Second dose reduction

100 mg/day* (one 100 mg capsule)

Dose Modifications for Non-Hematologic Adverse Reactions
Non-hematologic CTCAE* ≥ Grade 3 adverse • Hold ≤ 28 days or until
reaction where prophylaxis is not considered
resolution
feasible or adverse reaction persists despite
• Resume at a reduced dose
treatment
• ≤2 dose reductions
CTCAE ≥ Grade 3 treatment-related adverse
reaction lasting more than 28 days while
patient is administered niraparib 100
mg/day

• Discontinue medication

*If further dose reduction below 100 mg/day is required, discontinue

32

Niraparib [package insert]. Waltham, MA: Tesaro; 2019

Niraparib (Zejula®)
Dose Modifications for Non-Hematologic Adverse Reactions

Platelet count
<100,000/μL

Neutrophil
<1,000/μL or
Hemoglobin
<8 g/dL
Hematologic
adverse
reaction
requiring
transfusion

First occurrence:
• Hold ≤28 days and monitor blood counts weekly until platelet counts
↑≥100,000/μL
• Resume at same or reduced dose
• If platelet count is <75,000/μL, resume at a reduced dose
Second occurrence:
• Hold ≤28 days and monitor blood counts weekly until platelet counts
↑≥100,000/μL
• Resume at a reduced dose
• > 28 days of holding not resolved or already reduced to 100 mg po daily:
Discontinue
•
•
•
•

•

Hold ≤28 days and monitor blood counts weekly until neutrophil counts
↑≥1,500/μL or hemoglobin ↑≥9 g/dL
Resume at a reduced dose
If not acceptable >28 days from dose interruption period or already on 100 mg
po daily: Discontinue
Platelet count ≤10,000/μL: Consider transfusion
• Other risk factors such as co-administration of anticoagulation or
antiplatelet drugs: Consider interrupting these drugs and/or transfusion at
a higher platelet count
Resume at a reduced dose

*If myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) is confirmed, discontinue

33

Niraparib [package insert]. Waltham, MA: Tesaro; 2019

Niraparib (Zejula®)
Pearls
•
•
•

•

Nausea: Bedtime administration
Myelodysplastic syndrome/acute myeloid leukemia: Developed <2 months
to >4 years of therapy
Bone marrow suppression:
• Do not start until ≤ Grade 1 hematological toxicity
• Complete blood count
• First month: Weekly
• Next 11 months: Monthly and periodically
• Hematological toxicities do not resolve ≤28 days following
interruption: Discontinue and refer to hematologist
Cardiovascular effects: Monitor blood pressure and heart rate
• First 2 months: At least weekly
• First year: Monthly and periodically
34

Niraparib [package insert]. Waltham, MA: Tesaro; 2019

Androgen Receptor Inhibitors:
Enzalutamide (Xtandi®) and
Apalutamide (Erleada®)
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Patients with metastatic castration-sensitive prostate
cancer
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019
Enzalutamide [package insert]. Northbrook, IL: Astellas; 2019

Darolutamide (Nubeqa®)
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Patients with non-metastatic castration-resistant prostate
cancer
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019

Androgen Receptor Inhibitors
Dose

Darolutamide

600 mg (two
300 mg
tablets) po
twice daily

Strengths
•

300 mg

Drug-Drug Interactions
•
•

•

Combined P-gp and strong or
moderate CYP3A4 inducers: Avoid
Combined P-gp and strong CYP3A4
inhibitors: Monitor more frequently
for adverse reactions
BCRP substrates: Avoid, if not,
monitor for adverse reactions and
consider ↓ BCRP substrate drug
dose

240 mg (four
60 mg
tablets) po
daily

•

60 mg

•

Concomitant use with sensitive
substrates of CYP3A4, CYP2C19,
CYP2C9, UGT, P-gp, BCRP, or
OATP1B1: Avoid

160 mg (four
40 mg
Enzalutamide capsules) po
daily

•

40 mg

•

CYP2C8 inhibitors and CYP3A4
inducers: Avoid, if not, ↓to 80 mg
po daily
CYP3A4 inducers: Avoid, if not
possible, ↑ to 240 mg po daily

Apalutamide

37

•

Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019
Enzalutamide [package insert]. Northbrook, IL: Astellas; 2019

Androgen Receptor Inhibitors
Adverse Effects

Darolutamide

Apalutamide

•
•
•
•
•
•

Fatigue
Pain in extremity
Rash
Neutropenia
AST ↑
Bilirubin ↑

•

Ischemic
cardiovascular
events
Fractures
Falls
Seizure

•
•
•
•
•

Enzalutamide
•
•

38

Seizure
Posterior
Reversible
Encephalopathy
Syndrome (PRES)
Hypersensitivity
Ischemic heart
disease

Pearls
•
•

•

•

•

Missed dose: Take as soon as you remember. Do not
double up.
Should also receive a gonadotropin-releasing hormone
(GnRH) analog concurrently or should have had a
bilateral orchiectomy
Darolutamide:
• Take with food
• Twice daily
• ≥Grade 3 toxicity or an intolerable: Hold or ↓ to
300 mg po twice daily until symptoms improve 
may restart at 600 mg po twice daily
Apalutamide and enzalutamide:
• Seizure: Permanently discontinue
• Ischemic cardiovascular events: Optimize
management of cardiovascular risk factors
• Fractures: Refer to guidelines for use of bonetargeted agents
Enzalutamide
• PRES: Seizure, headache, lethargy, confusion,
blindness, and other visual and neurological
disturbances, ± associated hypertension
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019
Enzalutamide [package insert]. Northbrook, IL: Astellas; 2019

Oral Oncolytic Challenges
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There is a need to properly manage and monitor patients
who are self-administering their treatments at home
Presents challenges to health care providers and patients

Common misconceptions and safety issues regarding
oral oncolytics

Financial toxicity

Maximizing the efficacy of oral oncolytics
Oncology pharmacists are uniquely positioned to mitigate
these challenges

Weingart SN et al. 2008;6 Suppl 3:S1-14.

Handling
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Easily administered, however, have exposure risks, similar
to intravenous formulations
General misconception: Exposure risk is low and therefore
oral oncolytics present little risk and are safer to handle
Accidental exposure to oral oncolytics can occur at various
stages during handling

Storage

Handling

Administration

Disposal
Guidelines around safe handling are still evolving

Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068

Handling Recommendations for
Health Care Providers


Storage:

Store in a designated area separate from noncytotoxic
agents



Handling:
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Use personal protective clothing and equipment to
minimize exposure and health risks
Separate equipment should be used for cytotoxic and
noncytotoxic agents
Manipulations should be performed in a biological safety
cabinet
Should not be dispensed using automatic counting
machines

Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068

Handling Recommendations for
Health Care Providers
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Disposal and Cleaning of Contaminated Materials:

All disposable protective clothing and disposable:
Cytotoxic waste

All nondisposable materials: Wash or decontaminate
thoroughly after use
Training and Competencies for Safe Handling:

Orientation programs and routine training courses with
competencies on managing exposures and handling

A primary educator within a health care institution
should be established as a source of referral and
continued education on oral oncolytics

Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068

Handling Recommendations for
Patients and their Caregivers
Do’s
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Store according to package
insert
Keep in original container
Use gloves and wash hands
thoroughly before and after
glove application
Pour the oral chemotherapy
agent into a bowl, or the lid of
the pill bottle, and then pour
the pills into the patient’s
hand or mouth
Soiled items should be kept
and washed separately from
other laundry

Don’ts
Leave medication in open
areas, near sources of water,
direct sunlight
 Store medications in the
areas where food or drinks
are stored or consumed
 Crush, break, or chew tablets
 Discard medication down the
toilet or in the garbage


Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068

Financial Toxicity
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The advent of new options have improved patient outcomes

Accompanied with an increase in the monetary burden
of cancer treatment
Cancer has become the second most expensive disease in
the United States
Annual estimated cost estimated to increase from 124
billion dollars in 2010 to 157 billion dollars in 2020
Drug prices are a function of several factors

The cost of research and development

Manufacturing costs

Market pressures

Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28

Financial Toxicity
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Public and private payers have implemented cost sharing
measures that shift more of the financial burden to patients
Patients have been subjected to higher

Deductibles

Co-insurance

Copayments

Out-of-pocket (OOP) expenses
Patients with cancer have OOP expenses that are estimated
to be 976 to 1,170 dollars higher than patients without
cancer

Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28

Financial Toxicity
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Financial toxicity: Negative impact of a cancer diagnosis on
a patient's financial well-being resulting from direct or
indirect costs

Objective financial burden
• OOP expenses
• Indirect costs

Subjective financial distress
• Material conditions that arise from increased direct
and indirect costs
• The psychological response as a result of efforts
necessary to cope with the increased costs
• The coping behavior itself that patients adopt to
manage their medical care while experiencing
increased expenses
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28

Financial Toxicity
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Yabroff et al: 20.4% of adult cancer survivors reported
experiencing financial difficulties

Being unable to pay for their cancer-related medical bills

Having to borrow money

Going into debt

Filing for bankruptcy
To cope with financial toxicity, patients often resort to
medication nonadherence

Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28

Adherence
Variability in
adherence: 50100%
 Both over- and
under-adherence
can result in
Financial and
negative outcomes
Access

Higher mortality

Increased
toxicity

Delays and
changes in
treatment

Higher health
utilization and
48 total cost of care


Knowledge
Gaps
Adverse
Effects

Barriers to
Adherence

Weingart SN et al. 2008;6 Suppl 3:S1-14.

Barriers to Adherence: Financial
and Access
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Access barriers can be related to financial barriers
Examples:

Prior authorizations

High formulary tier

Quantity limits or not covered at all

Delays in receiving prescription
Solutions:

Dedicated medication assistance team

External financial assistance programs

Weingart SN et al. 2008;6 Suppl 3:S1-14.

Barriers to Adherence: Financial
and Access


Resources
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Manufacturer’s Patient Assistance Program
ACC Patient Assistance & Reimbursement Guide:
https://www.accc-cancer.org/home/learn/publications/patientassistance-and-reimbursement-guide
NCCN Virtual Reimbursement Resource Room:
https://www.nccn.org/reimbursement_resource_room/default.
aspx
CancerCare: www.cancercare.org
Cancer Family Relief Fund: www.cancerfamilyrelieffund.org
Cancer Finances: www.cancerfinances.org
Cancer Financial Assistance Coalition: www.cancerfac.org
Leukemia & Lymphoma Society: www.lls.org/support/financialsupport
Medicine Assistance Tool: www.medicineassistancetool.org
NeedyMeds: www.needymeds.org

Barriers to Adherence:
Knowledge Gaps
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Health literacy
May lack knowledge about

Administration schedules

Adverse effect management
Patient education program

Include family members or caregivers when possible

Patient-centered

Teach-back method

Provide information in multiple formats

Multiple times

Weingart SN et al. 2008;6 Suppl 3:S1-14.

Barriers to Adherence:
Knowledge Gaps
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Tips & Tools. LONSURF® (trifluridine and tipiracil) tablets. https://www.lonsurf.com/patient-resources/tools.

Barriers to Adherence:
Cognitive and Knowledge Gaps
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Solutions continued:

Multinational Association for Supportive Care in Cancer
(MASCC) Oral Agent Teaching Tool (MOATT):
https://www.mascc.org/assets/GuidelinesTools/moatt_v1.2.pdf

Dana-Farber oral chemotherapy fact sheet:
https://www.dana-farber.org/healthlibrary/articles/oral-chemotherapy-fact-sheet/

Counseling sheets: www.oralchemoedsheets.com,
www.chemocare.com

54
Darolutamide. OralChemoEdSheets. https://www.oralchemoedsheets.com/index.php/sheet-library/24-available/generic/357-darolutamide

55
Darolutamide. OralChemoEdSheets. https://www.oralchemoedsheets.com/index.php/sheet-library/24-available/generic/357-darolutamide

56
Darolutamide. OralChemoEdSheets. https://www.oralchemoedsheets.com/index.php/sheet-library/24-available/generic/357-darolutamide

Barriers to Adherence: Adverse
Effects
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Misconception: Adverse effects from oral oncolytics will be
less severe than side effects from intravenous therapy
May adjust their adherence to minimize adverse effects
Solutions:

Ensure patients, families, and caregivers understand
• Possible adverse effects
• How to manage adverse effects
• When and whom to call before stopping or altering
drug administration
• Address fears regarding reporting adverse effects

Managing side effects:
http://chemocare.com/chemotherapy/sideeffects/default.aspx
Weingart SN et al. 2008;6 Suppl 3:S1-14.

Barriers to Adherence: Adverse
Effects
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Managing Side Effects. Chemocare. http://chemocare.com/chemotherapy/side-effects/default.aspx.

Summary
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First oral oncolytics approved in 1953

Mercaptopurine, methotrexate
Proper precautions should still be taken when handling
Adverse effects are still possible
Increase in oral oncolytics

2019: 7 agents approved in 1 year
Advantages: Decreased trips to physician’s office or clinic
Disadvantages: Financial toxicity, minimal monitoring and
maximizing efficacy largely dependent upon patient
Solutions: Patient assistance programs/external programs,
education/counseling, calendars and other tools for
maximizing adherence
Weingart SN et al. 2008;6 Suppl 3:S1-14.
Tran G, Zafar SY. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28
Goodin S et al. J Oncol Pract. 2011;7(1):7–12. doi:10.1200/jop.2010.000068

References














60

Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral
chemotherapy. J Natl Compr Canc Netw. 2008;6 Suppl 3:S1-14.
Cabozantinib [package insert]. Alameda, CA: Elexisis; 2019
Trifluridine-Tipiracil [package insert]. Princeton, NJ: Taiho; 2019
Alpelisib [package insert]. East Hanover, NJ: Novartis; 2019
Erdafitinib [package insert]. Northbrook, IL: Astellas; 2019
Lenvatinib [package insert]. Woodcliff Lake, NJ: Eisai; 2019
Niraparib [package insert]. Waltham, MA: Tesaro; 2019
Darolutamide [package insert]. Whippany, NJ: Bayer; 2019
Apalutamide [package insert]. Guarbo, PR: Janssen Ortho LLC; 2019
Enzalutamide [package insert]. Northbrook, IL: Astellas; 2019
Goodin S, Griffith N, Chen B, et al. Safe handling of oral chemotherapeutic
agents in clinical practice: recommendations from an international
pharmacy panel. J Oncol Pract. 2011;7(1):7-12.
Tran G, Zafar SY. Financial toxicity and implications for cancer care in the
era of molecular and immune therapies. Ann Transl Med. 2018;6(9):166.
doi:10.21037/atm.2018.03.28

Questions

61

